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ABSTRACT 
Diabetes mellitus is a metabolic disease possi- 
ble to treat via pancreas/islet transplantation but 
most immunosuppressive drugs are diabeto- 
genic. In this letter, we review current up to date 
methods to assess insulin action and secretion 
(using the surrogate indexes) suggesting their 
use in large studies in populations of pancreas/ 
islets transplanted patients. 
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1. INTRODUCTION 
At present, pancreas and islet-cell transplantation are 
the only potential cure for type I diabetes, but long-term 
immunosuppression may produce several severe meta- 
bolic complications, such as glucose intolerance or overt 
diabetes. 
It is now 25 years since the antiproliferative and im- 
munosuppressive properties of rapamycin were first re- 
ported [1]. The latter effects were initially overshadowed 
by the former, and the agent was pursued more for its 
anticancer [2] than its potential transplantation effects. It 
is structurally similar to FK506, but unlike the cal- 
cineurin inhibitors, it has no effect on interleukin-2 pro- 
duction [3], despite clearly interfering with antigen- 
stimulated lymphocyte responses. The discovery that in 
vitro it would compete for the FK-binding protein and 
displace FK506 [4] gave rise to the misconception that 
the use of these two agents together would not be possi- 
ble. Furthermore, in literature rapamycin has been dem- 
onstrated its strong potency compared to other agents.  
Rapamycin is a potent inhibitor of endothelial injury 
in rat aortic allografts. When added to full-dose cyc- 
losporine it achieves low rejection rates, but it augments 
the nephrotoxicity and hyperlipidemia of cyclosporine. 
On the other hand, it allows discontinuation of cal- 
cineurin inhibitors in stable kidney and liver patients 
suffering from nephrotoxicity late posttransplant. At least 
in Caucasian patients, discontinuation of cyclosporine is 
possible as early as 3 months post-kidney transplant. In 
combination with low-dose tacrolimus, exceptionally 
low rates of rejection were seen in recipients of kidney, 
pancreas, and liver recipients with preservation of excel- 
lent renal function. These pilot studies have been con- 
firmed in several single-centre and, more recently, mul- 
ticentre trials in kidney and pancreas transplantation. The 
side-effect profile of hyperlipidemia, lymphocoeles, de- 
lay wound healing, and possibly liver effects are com- 
ing into focus, and ways of minimizing these problems 
are being introduced. The lessons learned include the 
need for early adequate blood levels, the lack of correla- 
tion between dose and drug exposure, and the potency 
that allows marked dose reductions in calcineurin in- 
hibitors and steroids [5]. The avoidance of steroidal im- 
munosuppressive drugs dramatically reduced the de- 
rangements of glucose metabolism. This was shown by 
our research group in other populations of organ trans- 
plant patients, such as liver [6] and kidney recipients [7]. 
Moreover, cyclosporine A is known both to impair insu- 
lin secretion and to decrease insulin action [8] and the 
nephrotoxicity is a major problem of this therapy [9].  
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2. METHODOLOGY  
We have recently shown that successful intraportal is- 
let transplantation can normalize hepatic glucose produc- 
tion and insulin action in type 1 diabetic patients with a 
kidney transplant [10]. This procedure is relatively safe, 
noninvasive (percutaneous puncture of the liver) and re- 
peatable, and it is performed in several centers world- 
wide [11,12]. The major factors limiting the large-scale 
application of islet graft in diabetic patients receiving 
chronic immunosuppression for a kidney graft are 1) the 
low percentage of patients reaching insulin independence 
and a complete normalization of glucose homeostasis 
[10]; and 2) the limited survival of fully successful grafts. 
Most diabetic patients receiving an islet graft achieve 
only partial function and a reduction of the pretransplant 
insulin requirement [11-16]; they are characterized by 
fasting C-peptide concentrations in the near-normal range, 
but frankly abnormal fasting glucose and glycosylated 
hemoglobin [11-14]. In the last decade, we [15,16] and 
others [17] found that protein and lipid metabolism had 
greater sensitivity to acutely infused insulin than did 
glucose metabolism, both in diabetes and uremia.  
The isoglycemic, hyperinsulinemic clamp is aimed to 
study the effect of insulin on glucose metabolism while 
glycaemia is maintained at the basal, pre-test level by 
means of an exogenous glucose infusion, whereas the 
hyperglycemic hyperinsulinemic clamp is considered the 
gold standard for the assessment of insulin secretion 
(Figure 1).  
The HOMA index (HOMA stands for homeostatic 
model assessment) measuring insulin sensitivity (HOMA- 
IS) is calculated as follows: HOMA-IS = 22.5/(gb × ib), 
where gb and ib are the basal glucose and insulin levels, 
respectively. The HOMA index measuring beta-cell se- 
cretion (HOMA-beta-cell) is calculated as follows: 
(HOMA-beta cell = 20ib/(gb-3.5). Over the recent years 
the popularity of the HOMA indexes has been boosted by 
a number of validation studies and has been gained a 
large success as the most economic way to measure 
concurrently insulin sensitivity and secretion [18]. 
Among the various dynamic tests that are available to the 
investigator, the oral glucose tolerance test has several 
advantages. It is very simple, it does not require trained 
personnel, the discomfort for the patient is minimized, 
the perturbation is physiological. The results are so 
promising that it can be envisioned that in few years the 
OGTT will become the method for the simultaneous as- 
sessment of glucose tolerance, insulin secretion and insu- 
lin sensitivity. As far as insulin secretion is concerned, 
one should bear in mind that during the OGTT the first- 
and second-phase insulin secretion are not clearly dis- 
tinguishable. What can be determined are two compo- 
nents of insulin secretion, namely the dynamic and the 
static components. The former component is related to 
the sensitivity of the beta-cell to the rate of change of 
glucose, while the latter component is related to the sen- 
sitivity of the beta-cell to the excursion of glucose (Fig- 
ure 2).  
An additional oral model (more physiological than the 
OGTT) is the mixed meal, which is able to asses both 
insulin sensitivity and beta cell function (by disposition 
index) like the OGTT [19].  
The IVGTT consists in rapidly injecting a bolus of 
glucose intravenously. The IVGTT allows the investiga- 
tor to clearly distinguish the first-phase insulin secretion  
 
Euglycaemic-Hyperinsulinemic Clamp 
 
Hyperglicaemic-Hyperinsulinemic Clamp 
 
Figure 1. Schematic representation of Euglycaemic-Hyperinsulinemic Clamp (upper 
panel) and Hyperglicaemic-Hyperinsulinemic Clamp (lower panel) with graphic rep- 
resentation of glucose and insulin plasma concentrations.  
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Meal Test and OGTT 
 
Figure 2. Meal Test and Oral Glucose Toler- 
ance Test (OGTT) with graphic representation 
of glucose and insulin plasma concentrations 
during these tests and models for determina- 
tion of insulin sensitivity and insulin action. 
 
and to calculate the glucose tolerance of the subject from 
the slope of the glucose decay curve. In addition, if the 
glucose bolus is followed at 20 min by an insulin bolus, 
the insulin sensitivity of the subject under study can be 
determined from the minimal model analysis of the glu- 
cose and insulin data sets. The IVGTT is more labor- 
intensive than the OGTT. The advantage of the IVGTT 
over the OGTT is that the first-phase of insulin response 
is clearly visible despite being more physiological (Fig- 
ure 3).  
3. DISCUSSION 
Successful pancreas transplantation has already been 
shown to correct the metabolic abnormalities of IDDM 
[7,20]. In 1996 our work demonstrated that intraportal 
islet transplantation (a procedure associated with a much 
lower morbidity) also normalized hepatic glucose pro- 
duction and improved tissue glucose utilization in a se- 
lected cohort of diabetic patients [21]. Moreover, a study 
conducted by our group demonstrated that two indices of 
insulin sensitivity (HOMA-IS and QUICKI) were reli- 
able measures of insulin sensitivity in kidney-pancreas 
transplanted patients [22].   
A recent paper showed in a multiethnic cohort of U.S. 
postmenopausal women that high HOMA-IR (insulin 
resistance) and low HOMA-beta-cell were independently 
and consistently associated with an increased diabetes 
risk. These data suggest the value of HOMA indexes for 
diabetes risk in epidemiologic studies [23].  
In type 2 diabetes, the loss of the early surge of insulin 
release, associated to insulin resistance, is an early and 
quite common defect that may have a pathogenetic role 
in the development of postprandial hyperglycemia [24]. 
Therefore in Pancreas and Islet transplanted patients is 
mandatory to have information about both insulin sensi- 
tivity and beta-cell function. In fact the early detection of 
graft dysfunction can facilitate the management of trans- 
planted patients for optimizing the anti-rejection thera- 
pies. The increasing need to keep the experimental costs 
as low as possible has given remarkable impulse to the  
IVGTT 
 
Figure 3. IntraVenous Glucose Tolerance Test (IVGTT) 
with graphic representation of glucose and insulin 
plasma concentrations during these tests and models 
for determination of insulin sensitivity and insulin ac- 
tion. 
 
use of surrogate indexes of insulin sensitivity and secre- 
tion derived from the measurements of glycemia and 
insulinemia obtained from a single blood sample drawn 
in the postabsorptive state. The indexes that championed 
this trend since from the beginning are the so-called 
HOMA indexes. Another study performed by our group 
showed that HOMA-IS and QUICKI (in comparison 
with isoglycemic, hyperinsulinemic clamp) are simple 
reliable tools to assess insulin sensitivity in clinical and 
epidemiologic investigations of chronic liver disease 
before and after LTx [25].  
An interesting review by Wallace and associated about 
the use and abuse of model for assessment of beta-cell 
function and insulin sensitivity showed that it is possible 
to use HOMA to assess insulin sensitivity in subjects 
treated with insulin, but it is imperative to ensure that 
samples are taken when glucose and insulin concentra- 
tions are in a steady state. Therefore this model does not 
apply when a subject is being treated with exogenous 
insulin. The use of HOMA in subjects on insulin needs 
further validation, and studies aiming at examining the 
use of HOMA under these circumstances are in progress 
[26].  
If the investigator needs a more accurate quantification 
of insulin secretion and insulin sensitivity, dynamic tests 
are mandatory. The burden for the clinical investigator 
and the discomfort for the patient increase, nevertheless 
the information gathered from this type of studies is 
more reliable than the one provided by the HOMA-in- 
dices, especially concerning insulin secretion.  
A recent paper by Cobelli and associates demonstrated 
that both IVGTT and meal tolerance tests could be used 
to illustrate how these different approaches would pro- 
vide complimentary yet differing insights regarding the 
regulation of beta cell function in humans [27].  
Most immunosuppressive drugs (if not all of them) 
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have metabolic effects and impair insulin action [28], 
acting at different levels in the postinsulin receptor sig- 
naling cascade and the final effector metabolic pathways 
of carbohydrate, protein, and lipid/lipoprotein metabo- 
lism. Prednisone is well known to induce insulin resis- 
tance with respect to glucose metabolism [7]. Both cyc- 
losporine and FK506 were shown by us to determine a 
modulation of insulin secretion and insulin action in 
liver-transplanted patients [29]. Rapamycin selectively 
inhibits the phosphorylation of p70 S6 kinase in vitro 
[30].  
The preexisting disease leading to organ transplanta- 
tion is important in facilitating the de novo development 
of diabetes mellitus. The worst theoretical condition re- 
gards patients already diabetic prior to transplantation. 
This is the rule for pancreas-transplanted patients and is 
quite common for kidney-transplanted patients who re- 
ceive the organ for end-stage diabetic nephropathy.  
In particular, the major metabolic advantage of the 
endocrine pancreas transplantation over other therapeutic 
modalities of treatment of Insulin-Dependent Diabetes 
Mellitus is that it represents a closed-loop system, with a 
secretory pattern elicited by glucose and other secre- 
tagogue stimuli.  
The assessment of insulin secretion is of paramount 
importance to evaluate the success of an islet graft, to 
monitor the beta-cell function as time elapses, to detect 
the early signs of rejection. Nevertheless, since glucose 
tolerance depends on both insulin secretion and insulin 
sensitivity, the combined assessment of insulin secretion 
and insulin sensitivity from the same clinical test would 
provide the investigator a more complete picture of the 
metabolic status of the transplanted patient.  
A different interesting consideration is that, independ- 
ently from the immunosuppressive therapy, the metabolic 
condition and the genetic background of the donor for 
pancreas and islet transplantation are important determi- 
nants for the success of the transplant itself and for the 
probability of developing metabolic alterations after or- 
gan transplantation.  
The easiest and consequently most popular assessment 
of beta-cell function is the homeostatic responsivity in- 
dex HOMA-beta-cell. The homeostatic model HOMA-IS 
provides also an index of insulin sensitivity, thus permit- 
ting the evaluation of beta-cell function in relation to the 
prevailing insulin action [27].  
In addition, the oral minimal model, using an OGTT 
or a mixed meal, can be used to measure beta cell func- 
tion, insulin sensitivity and hepatic insulin extraction of 
pancreas/islet transplanted patients.  
4. CONCLUSIONS 
A combination of hyperglycemic and euglycemic-hy- 
perinsulinemic clamp studies supplies the gold standard 
for quantifying of insulin sensitivity and beta-cell func- 
tion. However, clamp studies are expensive, complex to 
perform and require highly trained personnel [31]. 
The good markers for monitoring glucose metabolism 
in patients with pancreas and islet transplant are now 
disposable for all patients with simply blood basal sam- 
ple. In particular HOMA-IS, QUICKI and revised 
QUICKI are indexes of insulin sensitivity validated in 
many transplanted patients (liver and kidney-pancreas 
transplanted). Among the various dynamic tests, the 
OGTT and the mixed meal (able to assess both insulin 
sensitivity and beta cell function) are more appropriate in 
this category of transplanted patients than IVGTT.   
Therefore, HOMA-IS, HOMA-beta-cell, QUICKI and 
revised QUICKI are more simple and less invasive. In 
patients with pancreas and islet transplant, where glucose 
metabolism must be observed repeatedly during the first 
weeks after the allograft, these indexes were shown to be 
a reliable surrogate measure of in vivo insulin sensitivity/ 
secretion compared to the euglycaemic/hyperglycaemic 
clamp technique.  
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